Warning letter
Sanitor Corporation: warning letter of Nov 29, 2021
FDA warning letter 616232 · Division of Pharmaceutical Quality Operations IV
Key facts
| Reference number | 616232 |
|---|---|
| Company | Sanitor Corporation |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Nov 29, 2021 |
| Posted date | Dec 14, 2021 |
| Issuing office | Division of Pharmaceutical Quality Operations IV |
| Product type | Drugs |
| CFR sections cited | 201.61, 201.128, 207, 207.41, 211.22, 211.34, 207.41(c)(1), 207.41(c)(2), 211.68(b), 211.160(b) |
| Inspection city | Stanton |
| Inspection ZIP | 90680 |
| Inspection start date | May 25, 2021 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: